appScorecard
Performance
LowHasn't faired well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Biocon Ltd
BIOCON
Price Chart
Scorecard
Performance
LowHasn't faired well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Biocon Limited is a biopharmaceutical company engaged in the research & development and manufacture of pharmaceuticals, medicinal chemical and botanical products.
Brands
Investor PresentationView older
View Older PresentationsBrands
PeersCompare with peers
Hester Biosciences Ltd
Panacea Biotec Ltd
Zenotech Laboratories Ltd
Vivo Bio Tech Ltd
Transgene Biotek Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Increased Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has increased by 3.25%
Recent NewsAll news
Biocon Biologics may raise additional equity of $300 million in FY24 to pare debt
3 days ago•Economic Times
Biocon Q4 Results Review - Efforts Underway To Build Growth Levers Across Segments: Motilal Oswal
4 days ago•Bloomberg Quint
Biocon IPO after integration of Viatris market: MD & CEO Shreehas Tambe
4 days ago•Business Standard
Recent EventsAll events
Annual Secretarial Compliance Report
Pursuant to Regulation 24A of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, read with CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year 2022-23 dated May 23, 2023, issued by Mr. Pradeep B. Kulkarni, Partner of M/s. V. Sreedharan and Associates, Practicing Company Secretaries, Bengaluru. | Download
Pursuant to Regulation 24A of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, read with CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year 2022-23 dated May 23, 2023, issued by Mr. Pradeep B. Kulkarni, Partner of M/s. V. Sreedharan and Associates, Practicing Company Secretaries, Bengaluru. | Download
Cash Dividend
Final • Div/Share: ₹ 0.5
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant